CN1349406A - 含吗啉蒽环类化生物和抗癌剂的联合制剂 - Google Patents
含吗啉蒽环类化生物和抗癌剂的联合制剂 Download PDFInfo
- Publication number
- CN1349406A CN1349406A CN00806897A CN00806897A CN1349406A CN 1349406 A CN1349406 A CN 1349406A CN 00806897 A CN00806897 A CN 00806897A CN 00806897 A CN00806897 A CN 00806897A CN 1349406 A CN1349406 A CN 1349406A
- Authority
- CN
- China
- Prior art keywords
- drug
- topoisomerase
- inhibitor
- cancer
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
化合物 | 治疗方案 | 剂量(毫克/公斤/天) | ILS%3 | Tox4 | 统计分析二向方差分析 |
PNU-152243 | 静脉注射+1,2 | 0.05 | 50 | 0/10 | |
cDDP | 静脉注射+3 | 5.97.7 | 3333 | 0/10 | |
PNU152243+cDDP | 静脉注射+1,2静脉注射+3 | 0.055.9 | 83 | 0/10 | P=0.0034协同效应 |
PNU-152243+cDDP | 静脉注射+1,2静脉注射+3 | 0.057.7 | 100 | 0/10 | P=0.0036协同效应 |
Claims (59)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9909925.1 | 1999-04-29 | ||
GBGB9909925.1A GB9909925D0 (en) | 1999-04-29 | 1999-04-29 | Combined preparations comprising anthracycline derivatives |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2003101149119A Division CN1507869A (zh) | 1999-04-29 | 2000-04-04 | 含吗啉蒽环类化生物和抗癌剂的联合制剂 |
CNA2003101149091A Division CN1535688A (zh) | 1999-04-29 | 2000-04-04 | 含吗啉蒽环类化生物和抗癌剂的联合制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1349406A true CN1349406A (zh) | 2002-05-15 |
CN1222294C CN1222294C (zh) | 2005-10-12 |
Family
ID=10852508
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2003101149119A Pending CN1507869A (zh) | 1999-04-29 | 2000-04-04 | 含吗啉蒽环类化生物和抗癌剂的联合制剂 |
CNA2003101149091A Pending CN1535688A (zh) | 1999-04-29 | 2000-04-04 | 含吗啉蒽环类化生物和抗癌剂的联合制剂 |
CNA2006100597018A Pending CN1853645A (zh) | 1999-04-29 | 2000-04-04 | 含吗啉蒽环类化生物和抗癌剂的联合制剂 |
CNA2006100597037A Pending CN1853642A (zh) | 1999-04-29 | 2000-04-04 | 含吗啉蒽环类化生物和抗癌剂的联合制剂 |
CNB008068976A Expired - Fee Related CN1222294C (zh) | 1999-04-29 | 2000-04-04 | 含吗啉蒽环类衍生物和抗癌剂的联合制剂 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2003101149119A Pending CN1507869A (zh) | 1999-04-29 | 2000-04-04 | 含吗啉蒽环类化生物和抗癌剂的联合制剂 |
CNA2003101149091A Pending CN1535688A (zh) | 1999-04-29 | 2000-04-04 | 含吗啉蒽环类化生物和抗癌剂的联合制剂 |
CNA2006100597018A Pending CN1853645A (zh) | 1999-04-29 | 2000-04-04 | 含吗啉蒽环类化生物和抗癌剂的联合制剂 |
CNA2006100597037A Pending CN1853642A (zh) | 1999-04-29 | 2000-04-04 | 含吗啉蒽环类化生物和抗癌剂的联合制剂 |
Country Status (16)
Country | Link |
---|---|
US (2) | US6537990B1 (zh) |
EP (3) | EP1173187B1 (zh) |
JP (1) | JP2002543112A (zh) |
CN (5) | CN1507869A (zh) |
AR (1) | AR023616A1 (zh) |
AT (2) | ATE246507T1 (zh) |
AU (1) | AU4397700A (zh) |
DE (2) | DE60004348T2 (zh) |
DK (1) | DK1173187T3 (zh) |
ES (2) | ES2204572T3 (zh) |
GB (1) | GB9909925D0 (zh) |
HK (1) | HK1045462B (zh) |
MY (1) | MY136610A (zh) |
PT (1) | PT1173187E (zh) |
TW (1) | TWI222863B (zh) |
WO (1) | WO2000066093A2 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100500212C (zh) * | 2005-04-06 | 2009-06-17 | 山东蓝金生物工程有限公司 | 一种抗实体肿瘤药物组合物 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9916882D0 (en) * | 1999-07-19 | 1999-09-22 | Pharmacia & Upjohn Spa | Antitumor synergistic composition |
GB9920548D0 (en) * | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
ES2384789T3 (es) * | 2001-03-14 | 2012-07-12 | Bristol-Myers Squibb Company | Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas |
CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
US20080075762A1 (en) * | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
AU2002364051A1 (en) * | 2002-01-24 | 2003-09-02 | Children's Medical Center Corporation | Anti-cancer combination and use thereof |
TWI323662B (en) * | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
WO2004075904A1 (en) * | 2003-02-26 | 2004-09-10 | Pharmacia Italia Spa | Method for treating liver cancer by intrahepatic administration of nemorubicin |
WO2004082689A1 (en) * | 2003-03-18 | 2004-09-30 | Pharmacia Italia Spa | Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor |
NI200800032A (es) | 2005-07-25 | 2009-03-23 | Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20 | |
US7776832B2 (en) | 2006-04-21 | 2010-08-17 | Gem Pharmaceuticals, Llc | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines |
MX2008015524A (es) | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
US20090004134A1 (en) * | 2006-09-08 | 2009-01-01 | Obeid Michel Sarkis | Kit for treating a health condition by inducing translocation of an erp57 protein to a cellular membrane |
JP2010516741A (ja) * | 2007-01-29 | 2010-05-20 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | モルホリニルアントラサイクリンおよび抗体を含む抗腫瘍の組み合わせ |
WO2008138758A1 (en) | 2007-05-11 | 2008-11-20 | Nerviano Medical Sciences S.R.L. | Pharmaceutical composition of an anthracycline |
US20110021517A1 (en) * | 2008-02-26 | 2011-01-27 | Nerviano Medical Sciences S.R.L. | Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents |
SI2132228T1 (sl) * | 2008-04-11 | 2011-10-28 | Emergent Product Dev Seatle | CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom |
US8690833B2 (en) | 2011-01-31 | 2014-04-08 | Vascular Pathways, Inc. | Intravenous catheter and insertion device with reduced blood spatter |
KR20170110083A (ko) | 2014-12-23 | 2017-10-10 | 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 | 경피 투여를 위한 방법 및 제형 |
WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
US20190083527A1 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | Method of administration and treatment |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4710564A (en) * | 1985-01-18 | 1987-12-01 | Microbial Chemistry Research Foundation | Anthracycline compounds |
GB2172594B (en) * | 1985-03-22 | 1988-06-08 | Erba Farmitalia | New morpholino derivatives of daunorubicin and doxorubicin |
US5902809A (en) * | 1997-07-03 | 1999-05-11 | Paracure, Inc. | Arglabin compounds and therapeutic uses thereof |
GB9806324D0 (en) * | 1998-03-24 | 1998-05-20 | Pharmacia & Upjohn Spa | Antitumour synergetic composition |
GB9820012D0 (en) * | 1998-09-14 | 1998-11-04 | Pharmacia & Upjohn Spa | Use of an anthracycline derivative for the treatment of a liver tumor |
-
1999
- 1999-04-29 GB GBGB9909925.1A patent/GB9909925D0/en not_active Ceased
-
2000
- 2000-04-04 US US09/926,392 patent/US6537990B1/en not_active Expired - Fee Related
- 2000-04-04 AT AT00925158T patent/ATE246507T1/de not_active IP Right Cessation
- 2000-04-04 AU AU43977/00A patent/AU4397700A/en not_active Abandoned
- 2000-04-04 CN CNA2003101149119A patent/CN1507869A/zh active Pending
- 2000-04-04 DK DK00925158T patent/DK1173187T3/da active
- 2000-04-04 AT AT03075776T patent/ATE398457T1/de not_active IP Right Cessation
- 2000-04-04 CN CNA2003101149091A patent/CN1535688A/zh active Pending
- 2000-04-04 JP JP2000614978A patent/JP2002543112A/ja active Pending
- 2000-04-04 DE DE60004348T patent/DE60004348T2/de not_active Expired - Lifetime
- 2000-04-04 ES ES00925158T patent/ES2204572T3/es not_active Expired - Lifetime
- 2000-04-04 CN CNA2006100597018A patent/CN1853645A/zh active Pending
- 2000-04-04 CN CNA2006100597037A patent/CN1853642A/zh active Pending
- 2000-04-04 EP EP00925158A patent/EP1173187B1/en not_active Expired - Lifetime
- 2000-04-04 EP EP08157789A patent/EP1977753A1/en not_active Withdrawn
- 2000-04-04 WO PCT/EP2000/002923 patent/WO2000066093A2/en active IP Right Grant
- 2000-04-04 CN CNB008068976A patent/CN1222294C/zh not_active Expired - Fee Related
- 2000-04-04 PT PT00925158T patent/PT1173187E/pt unknown
- 2000-04-04 EP EP03075776A patent/EP1323423B1/en not_active Expired - Lifetime
- 2000-04-04 ES ES03075776T patent/ES2307867T3/es not_active Expired - Lifetime
- 2000-04-04 DE DE60039260T patent/DE60039260D1/de not_active Expired - Lifetime
- 2000-04-12 TW TW089106805A patent/TWI222863B/zh not_active IP Right Cessation
- 2000-04-26 MY MYPI20001780A patent/MY136610A/en unknown
- 2000-04-27 AR ARP000101989A patent/AR023616A1/es unknown
-
2002
- 2002-09-26 HK HK02107029.8A patent/HK1045462B/zh not_active IP Right Cessation
- 2002-10-31 US US10/284,144 patent/US6586428B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100500212C (zh) * | 2005-04-06 | 2009-06-17 | 山东蓝金生物工程有限公司 | 一种抗实体肿瘤药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN1853642A (zh) | 2006-11-01 |
AR023616A1 (es) | 2002-09-04 |
GB9909925D0 (en) | 1999-06-30 |
ATE398457T1 (de) | 2008-07-15 |
WO2000066093A2 (en) | 2000-11-09 |
EP1323423B1 (en) | 2008-06-18 |
US6537990B1 (en) | 2003-03-25 |
EP1173187A2 (en) | 2002-01-23 |
ES2307867T3 (es) | 2008-12-01 |
CN1535688A (zh) | 2004-10-13 |
EP1323423A1 (en) | 2003-07-02 |
CN1853645A (zh) | 2006-11-01 |
CN1222294C (zh) | 2005-10-12 |
HK1045462B (zh) | 2006-04-28 |
JP2002543112A (ja) | 2002-12-17 |
HK1045462A1 (en) | 2002-11-29 |
ES2204572T3 (es) | 2004-05-01 |
DE60004348T2 (de) | 2004-02-26 |
US6586428B2 (en) | 2003-07-01 |
WO2000066093A3 (en) | 2001-01-25 |
PT1173187E (pt) | 2003-10-31 |
ATE246507T1 (de) | 2003-08-15 |
DE60039260D1 (de) | 2008-07-31 |
DK1173187T3 (da) | 2003-10-20 |
US20030087839A1 (en) | 2003-05-08 |
TWI222863B (en) | 2004-11-01 |
DE60004348D1 (de) | 2003-09-11 |
AU4397700A (en) | 2000-11-17 |
MY136610A (en) | 2008-10-31 |
EP1173187B1 (en) | 2003-08-06 |
CN1507869A (zh) | 2004-06-30 |
EP1977753A1 (en) | 2008-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1222294C (zh) | 含吗啉蒽环类衍生物和抗癌剂的联合制剂 | |
ES2282400T3 (es) | Composiciones antitumorales que contienen derivados de taxano. | |
US6403563B1 (en) | Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate | |
CN1708296A (zh) | 抗癌组合 | |
CN101123966A (zh) | 包含使用et-743和多柔比星来治疗癌症的联合疗法 | |
EP1689404B1 (en) | Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer | |
MX2008014404A (es) | Tratamientos anticancer con combinacion de docetaxel y ecteinascidin. | |
CN1897949A (zh) | 包含使用et-743和紫杉醇来治疗癌症的联合疗法 | |
CN1302780C (zh) | 烷基胆碱磷酸在制备用抗肿瘤药之前和/或期间治疗肿瘤的药物中的应用 | |
CN1200712C (zh) | 用于治疗癌症的含喜树碱和1,2-二苯乙烯衍生物的组合物 | |
CN1168452C (zh) | 甲氧基吗啉代阿霉素在制备治疗肝肿瘤的药物方面的应用 | |
EP1200099B1 (en) | Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds | |
CN1391484A (zh) | 增强化疗疗效及治疗实体瘤的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NERVIANO MEDICAL SCIENCES S R Free format text: FORMER OWNER: PHARMACIA + UPJOHN S.P.A. Effective date: 20070727 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070727 Address after: Milan Italy Patentee after: Nerviano Medical Sciences SRL Address before: Milan Italy Patentee before: The Upjohn Co. |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051012 Termination date: 20110404 |